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The cellular basis of life has been known for nearly 150 years, but much 
remains to be learned about how cells function. BUSM scientists study 
the workings of ceii membranes in order to understand such disorders 
as Alzheimer's disease and cancer. See story on page 3. 
Felix Strumwasser, Ph.D., is studying a model system as a means of understanding basic 
mechanisms of circadian oscillators. (Photo by Bradford F. Herzog) 
BUSM researchers examine role of 
hormone abnormalities in hypertension 
it Is well established that abnormali-
ties involving hormones can lead to 
hypertension. 
An example is the steroid hormone 
aldosterone. Manufactured by the 
adrenal gland, aldosterone acts on 
the kidneys to promote salt retention. 
Normally, once salt levels have 
reached some equilibrium, the gland 
stops making the hormone. But cer-
tain circumstances can keep the 
shut-down from occurring, said 
James C. Melby, M.D., a professor 
of medicine and pharmacology at 
BUSM and an internationally 
known endocrinologist. 
"When the patient has an adrenal 
tumor or some other type of adrenal 
condition, the aldosterone can 
escape normal regulatory systems," 
explained Melby. 
The ongoing flow of aldosterone 
that ensues means that the kidneys 
are constantly being stimulated to 
retain salt, and the ultimate result is 
hypertension. "It has been shown 
that aldosteronism is the cause of 
high blood pressure in between one-
half and one percent of all hyper-
continued on page 5 
Biological clocks 
may provide 
clues to manic 
depression, 
other ailments 
The cycle of sleeping and waking, 
the regular rise and fall of body tem-
perature, and the daily program of 
hormonal activity are all familiar 
examples of human circadian 
rhythms—patterns of physiological 
activity that repeat on a roughly 
24-hour basis. 
Scientists have long recognized 
the occurrence of these phenomena 
but only recently have biomedical 
researchers begun to explore the 
clinical relevance of these rhythms. 
For instance, a recent report shows 
that heart attacks occur three times 
more frequently at 9 a.m. than at 
11 p.m. Similarly, a certain regimen 
of chemotherapy usually begun at 
6 p.m. for patients,with ovarian can-
cer is twice as likely to cause prob-
lems for the patient in terms of 
decreased tolerance and secondary 
infection as when the same treat-
ment is begun 12 hours earlier. 
In a normally functioning organism 
there are several physiological pro-
cesses that oscillate in the circadian 
range. (An oscillator is a mechanism 
that causes any function to change 
its value regularly over time; the 
period of the oscillator is the length 
of time required for the process to 
complete itself and start again.) 
continued on page 2 
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Biological clocks... 
continued from page 1 
In humans, the body-temperature 
cycle is an example of a strong oscil-
lator because it keeps close to a 25-
hour cycle even if the individual is 
completely shut off from normal envi-
ronmental time cues. Sleeping and 
waking, however, are governed by a 
weak oscillator because, after a few 
days or weeks of isolation, that cycle 
will break away to some extent from 
the body's temperature cycle. 
This implies that if, for some rea-
son, the internal body oscillators can-
not stay in tune with each other, then 
they can produce irregular beats. 
According to Felix Strumwasser, 
Ph.D., a BUSM professor of physiol-
ogy who is studying these rhythms 
on a cellular level, "There is a strong 
theoretical basis to believe that's 
what is happening in manic depres-
sive cycles." 
The drastic and devastating mood 
shifts of manic depression are rhyth-
mic in individuals with the disease 
but the periods of cycles vary from 
person to person, from a few weeks 
to a year. Under a five-year grant 
from the National Institute of Mental 
Health, Strumwasser is using a 
model circadian system and lithium, 
the agent used most successfully to 
manage manic depressive symp-
toms, to get at the basic mecha-
nisms involved in producing circadian 
oscillations. 
"The real question is, how do 
nerve cells that work in units of milli-
seconds generate patterns of activity 
in an organism that last 24 hours 
and that are repeated every day," 
said Strumwasser. 
To explore this question, Strum-
wasser and his former colleagues at 
California Institute of Technology 
several years ago discovered that a 
type of marine mollusk called a sea 
hare {Apiysia californica) has a 24-
hour "clock" built into its eye that is 
completely independent of the exter-
nal environment, although the timing 
of this clock can be entrained, or 
synchronized, by the environment. 
The animal, which looks like a fist-
sized snail without a shell, has eyes 
that produce optic nerve impulses at 
different rates at different times of 
day. Removed from the animal, the 
eye can be kept alive and active in a 
special medium for up to two weeks. 
Even if the isolated eye is kept in 
constant darkness, a record of its 
nerve activity over a two week period 
shows that the impulses continue to 
cycle normally, but slowly drift out of 
phase with the solar day. 
"Since the eye can be studied 
apart from the influences of other cir-
cadian oscillators, we can look at 
physiological, pharmacological and 
biochemical markers for this particu-
lar oscillator to get insights on how it 
produces this regular rhythm," 
explained Strumwasser. 
Strumwasser has found that lith-
ium introduced to the culture medium 
can lengthen the duration of the 
impulse cycle from its normal 24 
hours up to 33 hours, depending on 
the concentration used. Other 
agents, such as caffeine, lanthanum 
and manganese, have a similar 
effect. What all of these compounds 
have in common is the ability to 
interfere with calcium metabolism 
inside cells. 
"The working hypothesis is that the 
circadian oscillator is sensitive to 
internal calcium changes and, there-
fore, one suspects that any disease 
that might influence calcium in cells 
is going to perturb (the rhythm) and 
possibly produce a set of symptoms 
that may not have anything to do at 
all with the primary symptoms a 
physician is dealing with," Strumwas-
ser said. "The circadian oscillator 
itself does not have a special mecha-
nism for stabilizing those agents 
inside a cell that can affect it, but 
rather depends on other body pro-
cesses to regulate the agents." 
Strumwasser is pursuing studies of 
how circadian oscillators are gener-
ated in nerve cells in terms of their 
molecular and biochemical mecha-
nisms. He and former associate John 
C. Woolum, Ph.D., have found that if 
RNA metabolism is disrupted in cells 
either by x-rays or a drug such as 
actinomycin D, the rhythm of optic 
nerve impulses in the sea hare is 
abolished, although the eye remains 
otherwise healthy. "This was the first 
indication that circadian cycles in the 
eye appear to be dependent on a 
transcriptional event that occurs 
every day," said Strumwasser. 
He postulates that there is a set of 
proteins that modulate a cell's mem-
brane from the inside, across which 
nerve impulses are generated. Mem-
brane modulation is dependent on 
new proteins being made and 
degraded every day. If no new pro-
tein is manufactured because of 
drugs or radiation, then they cannot 
continue to influence the function of 
the membrane and the rhythm can 
no longer be expressed. 
The rhythm of nerve impulses in 
an isolated eye also can be sped up 
or slowed down depending on where 
in the cycle a perturbation is intro-
duced. Cyclic nucleotides such as 
cyclic AMP (adenosine 3', 5'-mono-
phosphate) and cyclic GMP (guano-
sine monophosphate) are agents that 
produce such phase shifts in the 
eye. "The evidence is fairly strong 
that cyclic AMP and GMP work 
through protein phosphorylation, a 
process by which the activity of a 
protein—whether in its role as a 
membrane channel or as an 
enzyme—can be turned on or off 
quickly. A pulse of cyclic AMP deliv-
ered to the eye produces a phase 
shift, which implies there is a change 
in the phosphorylation state of some 
key proteins to which the circadian 
oscillator is sensitive." 
Strumwasser, senior research 
assistant Daniel P. Viele, graduate 
student Daniel Kohane and former 
colleague George Stone, Ph.D., are 
using radioactive methionine (a com-
mon amino acid unit of proteins) to 
try to pinpoint which newly synthe-
sized proteins may be part of the cir-
cadian oscillator mechanism. 
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Cell membrane action may hold key to 
Alzheimer's and other disorders 
"We are looking at patterns of pro-
teins being synthesized in the eye at 
different times of the circadian cycle, 
and noting especially if there are 
some proteins that are made at one 
time and not at another. If so, these 
may be important regulatory agents 
of the oscillator itself or of the mem-
brane of the cell, or both." 
(Other evidence has suggested 
that the circadian mechanism may 
be located in the neurosecretory 
cells of the eye, which make proteins 
to be exported to different areas of 
the brain.) 
Much work, however, remains to 
be done at the basic molecular level 
to understand why lithium stabilizes 
manic depressive mood swings. 
Research on other biological prepa-
rations has demonstrated that lithium 
raises the levels of calcium inside 
different cells. Graduate student 
Mark Scanzillo is conducting experi-
ments in Strumwasser's lab to stabi-
lize internal calcium levels by using a 
calcium sequestering agent in order 
to determine if lithium will still be 
able to lengthen the circadian period 
of the eye. 
Concluded Strumwasser, "Basi-
cally, the body has a 'slow program' 
of activity that impacts on probably 
every physiological function. Only 
now are we starting to look at the 
clinical relevance of the circadian 
programs and beginning to gain 
insight into the basic mechanisms 
involved." 
—Caroline H. Lupfer 
Suggested Further Readings 
1. Woolum, J.C. and Strumwasser, P.: Is the 
period of the circadian oscillator in the eye 
of Apiysia directly homeostatically regu-
lated? J. Comp. Physiol. 757: 253-259, 
1983. 
2. Eskin, A. et. al.: Cyclic guanosine 3':5'-
monophosphate mimics the effects of light 
on a circadian pacemaker in the eye of 
Apiysia. J. Neuroscience 4: 2466-2471, 
1984. 
3. Woolum, J.C. and Strumwasser, P.: The 
differential effects of ionizing radiation on 
the circadian oscillator and other functions 
in the eye of Apiysia. Proc. Nat. Acad. Sci. 
USA 77: 5542-5546, 1980. 
Scientists have known for nearly 150 
years that the cell is the basic unit of 
all life, but they still don't fully under-
stand how it works. Researchers at 
Boston University School of Medicine 
are examining the intricate workings 
of cell membranes in an effort to bet-
ter understand the normal aging pro-
cess and such disorders as Alzhei-
mer's disease and cancer. 
Richard Fine, Ph.D., a cell biolo-
gist, is among the scientists at 
BUSM who are investigating the 
inner workings of normal cells, on 
the theory that these studies could 
offer insight into the functioning of 
abnormal cells. For a decade. Fine, 
a professor of biochemistry and an 
associate professor of physiology, 
has studied brain-, liver- and muscle-
cells of laboratory animals to learn 
how normal cells work and how the 
cells are regulated. 
"Once we know how a normal cell 
works, we will have an understand-
ing that we can apply to cells that 
don't function properly," said Fine. 
Funded by the National Institutes of 
Health, Fine's research centers on a 
tiny cell membrane with a very regu-
larly-shaped protein covering, the 
coated vesicle. Coated vesicles are 
derived from the plasma membrane, 
a lipid and protein envelope sur-
rounding the cell, and appear to play 
a role in regulating the internalization 
of material into cells. Fine believes 
that the coated vesicle may be the 
transport vehicle that carries mem-
brane proteins from place to place in 
cells. 
A large part of his work is devoted 
to discovering the number of mem-
brane transport steps in which the 
coated vesicle is involved. "Mem-
brane proteins seem to be made pri-
marily in one organelle (a specialized 
structure within a cell) and have to 
In studies of coated vesicles, Richard E. Fine, Ph.D., is learning how normal cells function and 
where breakdowns may occur in such disorders as Alzheimer's disease and cancer. (Photo by 
Bradford F. Herzog) 
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be distributed to all the different 
organelles in the cell," he explained. 
"The coated vesicle selects the pro-
teins to transport from one mem-
brane to another and leaves behind 
proteins it does not want to transfer." 
The process involves two major 
sorting decisions. From the millions 
of protein molecules in the mem-
brane, the cell selects the correct 
molecules to move from one mem-
brane to another. Then, after the 
molecules are removed from the 
membrane, the transport vesicle 
knows where to take those mole-
cules within the cell. 
Fine is most interested in the tar-
geting problem: how the coated vesi-
cle knows where to go in the cell. 
His lab has isolated coated vesicles 
in a highly purified form in brain-, 
liver- and muscle-cells. Although the 
coated vesicles from these three cell 
types all have the same type of coat-
ing, they carry different proteins. The 
protein determines the special func-
tion of each cell. 
However, Fine explained, all three 
cell types appear to make the protein 
acetylcholinesterase, an important 
enzyme. The brain produces this 
enzyme to control a chemical neuro-
transmitter, acetylcholine, which is 
involved in the transmission of impul-
ses between nerve cells. Muscle 
cells also produce this enzyme to 
prevent themselves from contracting 
too much. Scientists do not yet know 
why the liver manufactures the 
enzyme. 
Acetylcholinesterase appears to 
hold a key to determining which of a 
cell's two major pathways are 
involved in the transport of proteins. 
One pathway leads from inside the 
cell to the plasma membrane; the 
other pathway leads from the plasma 
membrane to inside the cell. Fine 
said information about the pathways 
may contribute to an understanding 
of Alzheimer's disease, in which a 
particular pathway in the brain, the 
cholinergic system, appears to 
become disordered and fails to func-
tion. 
Since aluminum and iron plaques 
have been found at the site of 
lesions in the brains of Alzheimer's 
patients. Fine is investigating the 
theory that such agents as toxic bio-
chemicals, viruses and, perhaps, 
large protein molecules, can enter 
the brain and interfere with normal 
cell function. To discover the path-
way these agents may take, he is 
studying in laboratory animals how 
iron, an essential molecule for all life, 
crosses the brain-blood barrier. 
"Endothelial cells at the blood-
brain barrier have receptors for 
transferrin, a protein in the blood that 
binds with iron," he theorized. "These 
receptors selectively take the trans-
ferrin with the iron into a vesicle. The 
vesicle then transports the iron-trans-
ferrin combination across the cell 
membrane, releasing it on the brain 
side of the cell membrane where it 
can be picked up by the brain cells 
that require it." 
In experiments with rats. Fine has 
used radioactive transferrin to suc-
cessfully demonstrate this selective 
receptor-mediated transport of the 
iron molecule from the blood into the 
brain. 
To better understand how liver 
cells grow and are regulated. Fine is 
conducting studies with Nancy 
Bucher, M.D., a professor of pathol-
ogy at BUSM and a leading expert in 
liver regeneration. Acetylcholinester-
ase and the coated vesicles in liver 
cells have played a significant role in 
their experiments. "Our ultimate 
goal," he said, "is to understand liver 
regeneration. 
"If we can understand what makes 
the normal cells stop at a given 
state, I think we're going to learn a 
lot that would relate to our under-
standing of cancer," said Fine. 
Bucher has shown that the quies-
cent liver of a normal rat, when stim-
ulated to divide, becomes "incredibly 
active." Nonetheless, the liver stops 
regenerating when it reaches approx-
imately normal size. Fine said, "We 
hope to isolate the proteins in the 
liver cell, put them into an artificial 
membrane, and study this process in 
order to understand how it is "turned 
on" and, very importantly, how it is 
"turned off." 
Coated vesicles carry the newly 
synthesized membrane proteins, 
which are necessary to build new 
proteins during liver regeneration. 
Fine is investigating whether more 
coated vesicles are mobilized when 
more cells are produced. 
In addition, Bucher has demon-
strated that the hormone vasopressin 
is required for liver regeneration. 
When vasopressin is released in a 
normal liver, the liver cells recognize 
the hormone and respond to it, but 
the liver is not 'turned on' to grow. 
When two-thirds of the liver is 
removed, however, this metabolic 
hormone changes to a growth factor, 
said Fine. 
Among those assisting with the 
liver research. Burton Dickey, M.D., 
an instructor in medicine, has suc-
ceeded in reconstituting and keeping 
active the vasopressin receptor so 
that it can be removed from its nor-
mal membranes and remain active. 
Colin Campbell, a graduate student, 
has had good results purifying phos-
phoinositide kinase, one of the key 
enzymes in liver regeneration. And 
Jordan Fishman, Ph.D., an assistant 
research professor of biochemistry, 
has discovered a protein in liver that 
appears to bind to two different hor-
mone receptors and to prevent them 
from binding further hormones. "It 
seems to be an important regulator 
of this class of hormones," said Fine. 
"We feel that we are making prog-
ress in our goals of characterizing 
this group of hormone receptors and 
regulators in metabolism and growth 
control," said Fine. 
—Shirley B. Moskow 
Suggested Further Readings 
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Hormone abnormalities... 
continued from page 1 
tensives," said Melby. 
Hypertension related to aldosteron-
ism often can be cured by treating 
the adrenal problem that brought it 
on. There are cases of hypertension, 
however, where the symptoms mimic 
those of the aldosterone-linked con-
dition but where there is no evidence 
of excessive amounts of the hormone. 
According to Melby, such cases 
suggest that hormones other than 
aldosterone play a role in hyperten-
sion. And after a quest spanning 
more than 15 years, he believes he 
has pinpointed one such hormone: 
19-nor-deoxycorticosterone, or 19-
nor-DOC. (The "19" refers to the 
position on a steroid hormone's car-
bon structure where a chemical com-
pound called a methyl group can 
attach. The "nor" signifies, however, 
that this particular steroid hormone 
has no methyl group at that spot.) 
In some ways, 19-nor-DOC is simi-
lar to aldosterone. It attaches to the 
same receptors in the kidneys, noted 
Melby, and presumably also boosts 
the tendency of those organs to 
retain salt. 
But the production of the two hor-
mones is not controlled in the same 
manner. In contrast to aldosterone, 
the levels of 19-nor-DOC do not rise 
and fall in response to increases and 
decreases in blood levels of the 
enzyme renin, which is manufactured 
in the kidneys. Instead, precursors of 
the hormone are made in the kid-
neys in response to signals from the 
pituitary gland, which is located in 
the brain. 
Although the extent of 19-nor-
DOC's role in hypertension is not yet 
known, the discovery that it does 
have a role has potentially vast impli-
cations. 
An estimated 60 million Americans 
have blood pressure that is at or 
above the level considered worri-
some: a systolic pressure of 140 and 
a diastolic of 90 (usually abbreviated 
to 140/90). Hypertension, moreover, 
has been identified by the Boston 
University-Framingham Heart Study 
as one of the three major risk factors 
for coronary disease, along with 
smoking and elevated blood levels of 
cholesterol. It also is implicated in an 
estimated 90 percent of strokes, and 
can cause heart failure, kidney fail-
ure and eye damage. 
According to Melby, 19-nor-DOC 
was first identified in the 1940s. In 
the last 10 years, he suspected it 
might be a culprit in some cases of 
hypertension. But when he looked for 
it in blood samples drawn from rats 
that had been selectively bred to 
exhibit a specific type of hyperten-
sion—a form of the disease that is 
linked to the animals' salt intake—he 
couldn't find any evidence of the hor-
mone. 
Later, he discovered why not. 
Unlike aldosterone, he explained, 19-
nor-DOC is not made in the adrenal 
gland. Instead, the gland produces 
precursors of the hormone. These 
then travel to various locations in the 
body, including the kidneys, and 
there are converted to 19-nor-DOC. 
The fact that the hormone is made 
in the kidneys suggested that it 
should be possible to test the urine 
for evidence of elevated levels. Mel-
by's group tried the technique in rats 
with salt-sensitive hypertension. As 
predicted, the animals had high lev-
els of 19-nor-DOC. 
"At that point, we started looking 
for 19-nor-DOC in urine samples 
from patients," he added, "and we 
found that it was significantly ele-
vated in a large proportion of salt-
sensitive hypertensives." 
Since those early findings, Melby's 
group has discovered various ways 
in which excessive amounts of the 
hormone might be generated. 
Crucial factors in the making of 19-
nor-DOC are the pituitary gland and 
its well-known product, adrenal corti-
cotropin hormone (ACTH). When the 
output of ACTH mounts—say, after 
an injury—it triggers an increase in 
the adrenal gland's production of the 
hormone Cortisol. That hormone then 
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travels to the injury site, helping to 
reduce the pain and to spur the 
arrival of infection-fighting white cells. 
The group's research suggests 
that one cause of excessive levels of 
19-nor-DOC is a breakdown in nor-
mal Cortisol metabolism. That hor-
mone is normally made through a 
series of steps that begins with cho-
lesterol, and involves the creation of 
several intermediate substances 
before the appearance of Cortisol 
itself. If something goes wrong with 
one of those steps, the end result 
may be the manufacture of other ste-
roid hormones, including 19-nor-
DOC. 
In fact, Melby's group has pin-
pointed what appears to be just such 
a breakdown. It is related to a lack of 
17a-hydroxylase, one of the 
enzymes involved in converting cho-
lesterol to Cortisol. 
"If you have a 17a deficiency, you 
get a decrease in Cortisol biosyn-
thesis," he explained. "Since there's 
less Cortisol to damp down the pitui-
tary, you get this continuing flow of 
ACTH, and that stimulates produc-
tion of other steroids, including the 
19-nor-DOC precursors." 
The 17a deficiency not only dis-
rupts Cortisol metabolism, but also 
inhibits the making of reproductive 
hormones. Thus, its symptoms 
include reproductive problems as 
well as hypertension. Men who lack 
the enzyme have poorly developed 
reproductive organs, said Melby, 
while women who are affected do 
not menstruate and cannot bear chil-
dren. 
The deficiency, which can be 
treated with substitute hormones, at 
best accounts for a miniscule propor-
tion of hypertension cases. Melby 
estimates that no more than 30 
Americans are affected by the condi-
tion. He also noted, however, that 
other things may go wrong with the 
cholesterol-cortisol pathway, leading 
to an excess of 19-nor-DOC. 
To find out more about 19-nor-
DOC's role in human hypertension, 
Melby and his associates are col-
laborating with investigators from 
Indiana and Louisiana on studies of 
large groups of hypertensives. At the 
same time, the BUSM investigators 
are looking for ways to treat or pre-
vent hypertension related to 19-nor-
DOC. 
One drug that shows promise, said 
Melby, is tamoxifen, which is widely 
used to treat breast cancer. It 
appears to work by blocking produc-
tion of the hormone. Another agent, 
developed in cooperation with inves-
tigators at the Massachusetts Insti-
tute of Technology, works by 
destroying one of the enzymes 
needed to create 19-nor-DOC. 
In any case, Melby is confident 
that if further research shows that 
19-nor-DOC plays a major role in 
hypertension, there will be no diffi-
culty identifying agents to deal with 
the problem. He also believes that if 
the excessive output of 19-nor-DOC 
starts shortly after puberty, as he 
suspects, it may be possible to pre-
vent the problem from causing 
hypertension. 
"If we could screen adolescents for 
19-nor-DOC," said Melby, "I believe 
we could interrupt this 19-pathway 
and prevent the individuals who are 
genetically prone to an excess of the 
hormone from ever being affected by 
it." 
Other investigators involved in this 
research include research associate 
Sidney L. Dale, Ph.D., and George 
T. Griffing, M.D., an assistant profes-
sor of medicine. 
—Richard P. Anthony 
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